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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 Sclerotherapy is an intravascular injection of a chemical irritant to 
cause chemical thrombophlebitis. The term was coined in the 1940's by 
American physician H. I. Biegeleisen[1]. Sclerotherapy is being used in 
treating varicose veins, hemangiomas and lymphangiomas. Introduced more 
than 150 years ago[2], sclerotherapy remains the most effective procedure for 
permanent eradication of pathologically enlarged as well as cosmetically 
undesirable but otherwise normal veins.  
 Innovative devices have been introduced within the past 10 years that 
utilize electromagnetic energy sources to target vein wall constituents 
directly or indirectly and either transcutaneously or intravascularly, but these 
procedures are significantly less effective and reproducible than 
sclerotherapy for permanently eradicating unwanted veins.  
 Foam sclerotherapy, in which the sclerosant is mixed with air or 
physiological gases, is more efficacious than direct injection of 
sclerosants[3], as air in the foam prolongs the contact of the agent with the 
endothelium. Hence, maximum sclerosant action can be obtained at lesser 
concentration and quantity. Foamed agent exerts its effect at 
microcirculation, which is inaccessible to other procedures. 
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AIM OF THE STUDY 
 
 
 
¾ To assess the effectiveness of foam sclerotherapy in various vascular 
and lymphatic malformations. 
 
¾ To observe the adverse effects of foam sclerotherapy during and after 
the procedure. 
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REVIEW OF LITERATURE 
 
 
VARICOSE VEINS 
Varicose veins literally mean grossly dilated, tortuous elongated 
veins. It can occur at different places in the body. The commonest is the 
varicosity of the lower limbs  
 
Etiology 
 The cause of primary varicose veins is incompetent venous valves that 
result in venous hypertension. Secondary varicose veins result from deep 
venous thrombosis and its sequelae or congenital anatomic abnormalities. 
The etiology of these varicose veins can be classified into the following 
three groups: 
• Primary: Valvular insufficiency of the superficial veins, most 
commonly at the saphenofemoral junction.  
• Secondary    
• Mainly caused by deep vein thrombosis (DVT) that leads to 
chronic deep venous obstruction or valvular insufficiency. 
Long-term clinical sequelae from this have been called the 
postthrombotic syndrome.  
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• Catheter-associated deep vein thromboses are also included.  
• Pregnancy-induced and progesterone-induced venous wall and 
valve weakness worsened by expanded circulating blood 
volume and enlarged uterus compresses the inferior vena cava 
and venous return from the lower extremities.  
• Intra-abdominal pressure / pelvic compression 
• Trauma 
• Congenital: This includes any venous malformations. A few examples 
are listed as follows:    
o Klippel-Trenaunay variants  
o Avalvulia 
Pathophysiology 
 Varicose veins are simply dilated, tortuous veins of the 
subcutaneous/superficial venous system. However, the pathophysiology 
behind their formation is complicated and involves the concept of 
ambulatory venous hypertension. To understand this, the anatomy of the 
lower extremity venous system must be briefly discussed. Two venous 
systems are found in the lower extremity, the deep and superficial. The deep 
system ultimately leads backs to the inferior vena cava, then to the heart. 
The superficial system is found above the deep fascia of the lower extremity, 
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within the subcutaneous tissue. Many superficial veins exist, but they all 
drain into the 2 largest, the greater saphenous vein (GSV) and the short 
saphenous vein (SSV), formerly called the lesser saphenous vein. 
 The superficial venous system is connected to the deep system at a 
number of the following locations: 
• Perforator veins: These veins transverse the deep fascia of the lower 
extremity. A number of named perforators are found at the thigh, 
knee, and leg.  
 
Named perforators along the greater saphenous distribution. 
• Saphenofemoral junction (SFJ): This is located proximally at the 
groin where the GSV meets the femoral vein. 
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          Saphenofemoral junction. 
• Saphenopopliteal junction (SPJ): This is located behind the knee 
where the SSV joins with the popliteal vein. 
In healthy veins, the flow of venous blood is through the superficial system 
into the deep and up the leg and toward the heart. One-way venous valves 
are found in both systems and the perforating veins. Incompetence in any of 
these valves can lead to a disruption in the unidirectional flow of blood 
toward the heart and result in ambulatory venous hypertension. Furthermore, 
incompetence in one system can often lead to incompetence in another.  
 Incompetence in the superficial venous system alone usually results 
from failure at valves located at the SFJ and SPJ. The gravitational weight of 
the column of blood along the length of the vein creates hydrostatic pressure, 
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which is worse at the more distal aspect of the length of vein. 
 Incompetence of the perforating veins leads to hydrodynamic 
pressure. The calf pump mechanism helps to empty the deep venous system, 
but if perforating vein valves fail, then the pressure generated in the deep 
venous system by the calf pump mechanism are transmitted into the 
superficial system via the incompetent perforating veins.  
 Once venous hypertension is present, the venous dysfunction 
continues to worsen through a vicious cycle. Pooled blood and venous 
hypertension leads to venous dilatation, which then causes greater valvular 
insufficiency. Over time, with more local dilatation, other adjacent valves 
sequentially fail, and after a series of valves has failed, the entire superficial 
venous system is incompetent. As mentioned before, this can then cause 
subsequent perforator and deep venous valvular dysfunction. 
 
 
 
 
 
 
7 
VALVES IN THE VEINS 
   
    
    
       
Normal vein with unidirectional valve 
Unidirectional valve (Prevents backward flow)
 Varicose vein with damaged valves 
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Pathway leading to varicose veins  
 
 The inciting etiology of superficial valvular insufficiency is 
often difficult to determine because the clinical manifestations of venous 
hypertension are delayed. The original cause can be classified as primary, 
secondary, and congenital as previously described. 
 The clinical finding of varicose veins, reticular veins, and 
telangiectasias are due to the hypertension in the superficial venous system 
that spreads to collateral veins and tributary veins, causing dilated tortuous 
structures. Treatment modalities are geared towards correcting the 
superficial venous hypertension [4]. In contrast to the superficial veins, the 
deep veins do not become excessively distended. They can withstand the 
increased pressure because of their construction and the confining fascia. 
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Predisposing factors 
Age: As age advances the frequency of the disease increases 
Sex: Most commonly seen the female population 
Racial 
Hereditary Factors 
Hormonal: Female hormone 
Pregnancy: Pressure of gravid uterus on the major veins in the abdomen 
Secondary to Diseases: Fibroid Uterus, Lower abdominal tumors 
Secondary to Deep Vein Thrombosis  
Chronic Constipation 
Occupational: Standing for prolonged period 
 
Symptoms : 
Pain: Dull aching pain in the lower leg is the commonest early symptom 
Swelling of the feet: Oedema of the feet especially on standing for long time 
or by evening is the next common symptom. 
Bleeding 
Itching  
Discoloration: Blackish discoloration around the ankle joints and lower leg 
Eczematous Change around the ankle and foot 
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Lipodermatosclerosis: Thickening of the skin with depigmentation or hyper 
pigmentation 
Venous ulcers: Initially small ulcers develop and heal spontaneously over a 
period of time. Later small ulcers refuse to heal and proceed to progressive 
skin erosion resulting in very large non healing ulcers  
Investigations: 
           In addition to the routine investigations, the specific investigation is a 
Color Doppler Scan of the Lower Limb Venous System. The main purpose 
is to rule out any deep venous thrombosis. 
Treatment of Varicose Veins: 
There are different modalities of treatment for varicose veins: 
1) Surgery:  
i. This is the conventional treatment directed towards the ablation of the 
diseased veins by dissection i.e., Ligation of the feeding vessels at the 
inguinal region followed by Stripping of the superficial vein.  
ii. Multiple subfascial ligation by different techniques/invasive as well as 
minimally invasive techniques.  
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iii. Valvoplasty: Reconstructing artificial valves in the veins, a very 
tedious as well as expensive procedure.  
2) Minimally invasive Procedures 
     (a) Electrodessication:  
This is the process of passing electric current through a probe to destroy the 
vessel wall but is rarely used today because of the disfiguring cutaneous 
injury. 
     (b) Radiofrequency ablation  
Thermal energy is delivered directly to the vessel wall, causing protein 
denaturation, collagenous contraction, and immediate closure of the vessel. 
In contrast to laser therapy, the RF catheter actually comes into contact with 
the lumen walls. 
 (c) Endo venous Laser Ablation (ELT)  
A laser fiber produces endoluminal heat that destroys the vascular 
endothelium.  
    (d) Sclerotherapy: 
            The oldest, simplest and the cheapest method of treating varicose 
veins, the most accepted and promising method of treatment by constant 
innovations in the technique. It takes hardly 10 to 15 minutes for the 
completion of the procedure. 
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HEMANGIOMAS AND LYMPHANGIOMAS : 
 
Vascular tumors and malformations have often been described using a 
classification system based on morphologic characteristics. This practice has 
given rise to a countless number of names that are interchangeably used, 
often befuddling medical professionals. In 1982, Mulliken and Glowacki 
proposed a biologic classification of vascular tumors and malformations that 
has since gained wide acceptance [5]. This system correlates histologic 
features with historical and physical findings to provide a simplified 
classification of vascular lesions. The system has been modified slightly 
over the years to incorporate new information. 
Mulliken and Glowacki use the following criteria to separate vascular 
malformations into 2 broad categories: 
• Vascular tumors are also known as hemangiomas. These tumors 
exhibit endothelial hyperplasia. Approximately 30% are visible at 
birth, and the remaining 70% appear in children aged 2-4 years. 
Postnatal growth is rapid, and involution is slow. In 1996, the 
International Society for the Study of Vascular Anomalies added the 
rapidly involuting congenital hemangioma, non-involuting congenital 
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hemangioma, Kaposiform hemangioendothelioma, tufted angioma, 
and pyogenic granuloma to the list of vascular tumors.  
• Vascular malformations are subdivided into high-flow (arterial, 
arteriovenous) malformations and slow-flow (venous, capillary, 
lymphatic) malformations. They exhibit normal endothelial turnover. 
Approximately 90% are recognized at birth. They increase in size as 
the child grows. 
Frequency 
Vascular tumors (i.e., hemangiomas) are the most common tumors in 
infants. They are apparent in 1-2.6% of neonates at birth across all races, 
according to one series. Approximately 30% of hemangiomas are recognized 
in the newborn nursery. Prevalence is increased in preterm infants that 
weigh less than 1000 g and in white children younger than 1 year. The male-
to-female ratio is 3:1  
The incidence rate of lymphatic malformations is 1.2-2.8 per 1000 
live births [6]. Approximately 50% of lymphatic malformations are apparent 
at birth; 90% appear before age 2 years. Most reports indicate an equal male-
to-female distribution. 
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Etiology 
Vascular tumors (hemangiomas) are believed to result from 
developmental errors that occur at 4-10 weeks’ gestation. Most cases are 
sporadic; however, they are occasionally inherited in an autosomal dominant 
fashion with moderate-to-high rates of penetrance [7]. 
Capillary malformations are generally considered to be sporadic 
lesions; however, pedigrees of autosomal dominant inheritance have been 
reported. Port-wine stains are also associated with Klippel-Trenaunay-
Weber and Sturge-Weber syndromes. Mutations in the RASA1 gene may 
underlie the capillary malformation–arteriovenous malformation syndrome. 
A novel mutation in RASA1 has been reported to cause capillary 
malformation and limb enlargement [8]. An extensive degree of phenotypic 
heterogeneity may be associated with deleterious mutations in RASA1. 
The exact cause of lymphangioma formation is unknown, but most 
cases are believed to be sporadic. The formation of lymphangiomas possibly 
reflects a failure of lymph ducts to connect with the venous system during 
embryogenesis, abnormal sequestration of lymphatic structures, or both. 
Ongoing research has elucidated some of the vascular growth factors that 
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may be involved in formation of lymphatic malformations such as VEGF-C 
and flt-4. Cases secondary to trauma and infection have also been reported. 
Pathophysiology 
Hemangiomas are the result of abnormal changes in angiogenesis that 
allow the overproliferation of vascular entities. Several authors have 
elucidated the complex interplay of angiogenic and angiostatic forces 
involved in normal and pathologic processes [9]. However, fetal vascular 
development remains poorly understood. Many of the angiogenic markers 
(i.e., FGF, VEGF, E-selectin, type IV collagenase) are increased during the 
proliferative phase [10].  
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During the involutional phase of hemangiomas, a subsequent decrease 
in angiogenic factors occurs, with a 5-fold increase in endothelial cell 
apoptosis. These alterations in angiogenic factors may account for the 
increased vascular proliferation that occurs in hemangiomas. Mesenchymal 
progenitor cells may be key to infantile hemangioma development [11]. These 
hemangiomas may be caused by an abnormal or delayed differentiation of 
mesodermal progenitor cells into the disorganized mass of blood vessels. 
Microscopic hemangioma tissue reveals proliferating endothelial 
cells. During involution, endothelial cells flatten, the vessel lumens dilate, 
and fibrous tissue is deposited. Recent studies have also discovered 
hemangioma-specific antigens not found in normal skin. These include 
GLUT1, merosin, and Lewis Y antigen. 
Capillary malformations (port-wine stains) are groups of tortuous 
blood vessels located in the upper layers of the dermis. One study revealed 
that these lesions have decreased innervation in perivascular regions, which 
generates the hypothesis that the lesions are secondary to impaired vascular 
tone.  
Lymphangiomas are collections of lymph vessels filled with serous 
fluid. Their histology ranges from capillary-sized vessels to macroscopic 
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fluid–filled vessels. Lymphatic malformations can be associated with gross 
anatomic deformities with severe involvement of the surrounding structures 
on the face or extremities. Research has begun to reveal some of the cell 
signals that may be involved in the formation of lymphangiomas. For 
example, VEGF-C has been found to be adequate in causing lymphatic 
hyperplasia. Evaluation of VEGF-C and VEGFR-3 in a series of 
lymphangiomas has suggested that superficial lymphangiomas likely 
represent peripheral lymphatic dilatation [12]. 
Presentation 
Hemangiomas are most commonly located on the head and neck 
(59%), followed by the trunk (24%), lower extremities (10%), and upper 
extremities (7%) [13]. Most are less than 2 cm in diameter but, in some 
instances, can cover large portions of the body. Typical presenting 
symptoms occur superficially, and the appearance can vary from a 
hypopigmented macule to a bruiselike macule [14]. The course of these 
lesions includes a proliferative postnatal growth phase that lasts for 3-9 
months, with a gradual involution that occurs over 2-6 years. Involution is 
usually complete by age 7-10 years. Only 50% of patients have completely 
normal-appearing skin at this time. 
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Recognizing atypical presentations and sub classifications of 
hemangiomas is critical for prognostic and treatment purposes. A congenital 
hemangioma is a lesion that is fully developed at birth. Deep hemangiomas 
have a blue discoloration because of their proliferation in the dermis and 
subcutaneous tissues. Multiple hemangiomas, often referred to as 
hemangiomatosis, appear as multiple smaller lesions. Pseudoclubbing may 
be the first sign of an underlying subungual hemangioma.  
Because hemangiomas may be a part of a syndromic complex, query 
about other symptoms that may be associated with Klippel-Trenaunay-
Weber or Sturge-Weber syndromes. The triad of Klippel-Trenaunay-Weber 
syndrome symptoms includes vascular tumors of the limbs, trunk, or 
perineum; varicose veins; and bony and/or soft tissue hypertrophy of the 
extremities. The presenting symptom in patients with Sturge-Weber 
syndrome is often a facial lesion, most commonly a nevus flammeus located 
in the V1-V2 dermatomes. Other findings include a history of epileptic 
seizures, hemiplegia, visual field defects, and glaucoma 
Most lymphangiomas are clinically apparent at birth, and almost all 
are apparent by age 2 years. Most appear as soft doughy masses that are 
located in the head and neck region, and most have no associated symptoms. 
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Clinical manifestations are dependent on the flow of lymph within the 
channels of the lesion. Lymphangiomas may manifest as lymphedema, and 
larger lesions can involve the skeletal system and cause gross disfigurement. 
Large malformations in the neck or mediastinum can compromise the 
airway, leading to stridor, dysphonia, or dyspnea. Lymphangiomas have also 
been found in patients with Turner syndrome, Klinefelter syndrome, and 
Noonan syndrome 
Treatment  
I. Medical Therapy 
Vascular tumors 
Approximately 75% of hemangiomas involute without intervention 
and are in anatomically benign locations, making them a cosmetic issue. 
Regular follow-up visits should be scheduled to monitor the course of the 
lesion and to provide continuous reassurance to the parents. 
Medical intervention is indicated if hemangiomas are located in areas that 
hinder normal development, interfere with important life processes, or cause 
severe pain. Such locations include the eye, nose, and airways. Current 
practices include the following: 
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• Systemic glucocorticoids are the first-line therapy for lesions that are 
life threatening or cause severe deformity. Efficacy rates have been 
reported at 84% with prednisone equivalent doses of 2.9 mg/kg if 
administered during the proliferative phase [15].  
• Triamcinolone is indicated for smaller hemangiomas; intralesional 
injections administered every 4-6 weeks have been shown to result in 
faster rates of involution in 30% of patients.  
• Interferon alfa-2a is used for life-threatening or deforming lesions that 
do not respond to glucocorticoid therapy. It is subcutaneously 
administered at a dose of 1-3 million U/m2 of body surface area [16]. 
• Flashlamp-pumped PDL is indicated for superficial residual lesions 
that remain after involution; this is not effective on deep 
hemangiomas. Recent studies show no advantage to early laser 
intervention versus conservative treatment.  
Lymphatic malformations 
For localized lymphatic malformations, various pharmacologic agents 
have been used around the world to treat lymphangioma. Some of the agents 
used are sclerotherapy using boiling water, tetracycline, bleomycin, and 
cyclophosphamide. Sclerotherapy may also be of value in venous 
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malformations, acquired digital arteriovenous malformations, and 
hemangiomas [17].  
II. Surgical Therapy 
Surgical excision of vascular tumors (hemangiomas) is controversial 
because most lesions involute with little intervention (75%). 
Surgery is indicated if the procedure is anticipated to leave a scar that 
is more cosmetically acceptable than a scar due to medical therapy or 
following involution. Furthermore, in the following few specific situations, 
surgical intervention is considered inevitable if :  
(1) An abnormal scar or excess tissue is present after natural involution;  
(2) Lesions are ulcerated and bleed excessively or are associated  with pain;  
(3) Lesions interfere with the development or activities necessary for life, 
such as lesions of the eye, ear, or larynx. 
Lymphatic malformations 
Surgical excision for localized lymphangioma if anatomically 
possible, with total removal of the tumor, leaving behind no cystic 
epithelium, has been the most reliable procedure. In one study, total 
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resection led to no recurrences following the procedure. This is compared 
with recurrences in 6 of 7 patients if excision of only protruding cystic 
epithelium was performed.  
SCLEROTHERAPY  
MECHANISM OF ACTION : 
Sclerotherapy is the procedure in which chemical energy is used to 
eradicate a vessel. The chemical energy delivered intravascularly is capable 
of denaturating biological molecules that comprise the vein wall. For 
permanent eradication of the vein, it is necessary to produce full mural 
denaturation or atleast enough mural injury requisite to preclude mural 
reconstitution. If this is attained, the mural layers will be resorbed, and the 
lumen that is surrounded will be obliterated. The vein will permanently 
disappear. The persistence of a vein after treatment is evidence that full 
mural denaturation was not achieved. 
 Sclerotherapy targets the mural constituents and not the blood in the 
vein lumen. Although is unnecessary and undesirable, thombosis almost 
always develops within the lumen of every treated vein. This is because, 
once infusion of the sclerosant is terminated, some blood returns into the 
lumen, which at that time is still intact even though full mural denaturation 
may have been attained. The presence of sub endothelial collagen and other 
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coagulation cascade initiators causes the blood to coagulate (i.e., 
thrombose). Thrombosis does not affect the extent of mural denaturation and 
does not usually affect the ultimate outcome of treatment [56]. However it 
prolongs the course of vein resorption and thus the duration for its eventual 
disappearance. 
 To limit endothelial injury to a controlled area, we exploit differences 
in flow dynamics between the abnormal veins being perfused with sclerosant 
and the adjacent normal vessels that should not be sclerosed. A thorough 
understanding of the mechanism of action of the principal sclerosing agents 
is essential, as is a firm grasp of the biophysical principles underlying the 
techniques of sclerotherapy.  
Volume dilution and patient positioning[18] 
 Sclerosant is diluted with blood as it diffuses away from the site of 
injection, thus if a strong sclerosant is injected there will be three zones of 
action. In zone 1, vascular endothelium is irreversibly injured: the vessel will 
be fully sclerosed and eventually will be completely replaced by a fibrous 
tissue. In zone 2, vascular endothelium is injured, and the vessel will be 
partially or completely thrombosed but will eventually recanalize. In zone 3 
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the sclerosant will be diluted below its injurious concentration, and there 
will be no endothelial injury.  
Dilution by diffusion from the injection site[18] 
 Because dilution of the sclerosant with blood occurs immediately 
upon injection, the original injected concentration is of no real importance. 
What is important is the diluted concentration of sclerosant at the surface of 
the endothelium. An injected concentration that is perfectly effective in a 
spider vein (where sclerosant displaces blood rather than mixing with it) 
may be ineffective in a reticular feeding vein or a truncal varix simply 
because dilution reduces the final concentration so low that there will be no 
endothelial injury whatsoever (no zone I or zone II). If the injected 
concentration is too high, dilution will leave the final concentration so high 
that endothelial damage will occur where it is not wanted (zone I and zone II 
are too large). If the injected concentration is just right, dilution will leave a 
final concentration that is sufficient to injure the local varicose endothelium, 
but not high enough to damage normal superficial or deep veins (most of the 
varicose vessel falls into zone I, a small amount falls into zone II, and all 
normal vessels fall into zone III).  
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 When we select a particular volume and concentration of a chemical 
agent with which to sclerose a vessel, we are explicitly or implicitly 
adjusting the injected concentration and volume to take into account the 
dilution that will occur when the sclerosant is mixed with blood immediately 
after injection. We also must take into account the further dilution that will 
occur as the sclerosant flows or diffuses away from the site of injection. The 
importance of patient positioning in determining dilutional volume often is 
not properly appreciated by the novice in phlebology.  
 Because of the cylindrical geometry of blood vessels, the volume 
contained in a vessel depends on the square of the vessel radius: the volume 
of any cylinder is calculated as pi * r2 * L (where r is the radius and L is the 
length of the vessel). Vessels collapse to a smaller radius when the legs are 
elevated, thus the volume contained is reduced dramatically. For this reason, 
the position of the patient has a very powerful effect on the final diluted 
concentration of sclerosant at the surface of the vessel endothelium.  
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EFFECT OF POSITION ON VARICOSE GEOMETRY[18]  
¾  Standing 
 For a standing patient with a superficial varicosity of 2 cm in 
diameter, the final concentration at a distance from the injection site of 10 
cm (4 inches) is 30 times lower than the initial concentration. Doubling the 
initial concentration serves only to double the final concentration, which will 
still be 15 times weaker than the concentration in the syringe. In other 
words, if 1 cc of a 3% solution is injected, the final concentration at the 
endothelial surface is 1% at a distance of 1 cm from the injection point, 
0.5% at a distance of 2cm, 0.25% at a distance of 4 cm, and 0.2% at a 
distance of 5cm (2 inches) from the injection point. As we shall see, this 
means that it is very difficult to achieve sclerosis of a large vessel by 
injecting detergent sclerosants with the patient in a standing position: if the 
highest available concentration is injected, the dilution factor may still drop 
the final concentration below the threshold of effectiveness within 1.5 inches 
from the injection site.  
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¾ Supine 
 Varicose vessels that bulge when the patient is standing may collapse 
when the patient is supine, but duplex ultrasound readily demonstrates that 
the veins are not empty of blood. Both varicose and normal vessels contain a 
significant volume of blood with the legs extended in the supine position. A 
bulging varicosity that has a diameter of 2 cm in the standing position may 
have a diameter of 1 cm in the supine position and of 0.5 cm or less when 
the legs are elevated as high as possible. With such a patient in the supine 
position, injection of 1 cc of a 3% solution leads to a final concentration of 
approximately 1.7% at a distance of 1 cm and a concentration of about 0.6% 
at a distance of 5 cm (2 inches). This supine technique limits dilution enough 
to allow successful sclerosis of large vessels using detergent solutions, so 
long as sufficient concentrations and volumes of sclerosants are injected. 
The only problem is that if an injection of sclerosant at a high initial 
concentration is made directly into a perforating vessel, so that sclerosant 
flows directly into the deep system, dilution within the deep vessel will still 
permit zone I and zone II endothelial injury for a short distance within the 
deep vein. This can lead to deep vein valve damage and chronic venous 
insufficiency, to deep vein thrombosis, and to life-threatening pulmonary 
embolism.  
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¾  Legs elevated 
 In contrast to the standing and supine positions, when a patient lies 
supine and the legs are raised vertically so that they are well above the 
central circulation, most superficial varices collapse to the point where they 
no longer contain any significant volume of blood. Repeating the calculation 
above for a patient in this position, injection of 1cc of a 3% solution leads to 
a final concentration of 2.5% at a distance of 1 cm from the injection, and a 
final concentration of 1.6% at a distance of 5 cm (2 inches). In fact, the final 
concentration will still be above 1% at a distance of 10cm from the injection 
site. Because the superficial varicosity is collapsed, there is very little 
dilution with distance so long as the sclerosant stays within the floppy-
walled varicosity.   
 Although flow measurements reveal little or no spontaneous flow 
through varices and smaller superficial veins when the patient is in the leg-
up position, a substantial intravenous volume and a substantial rate of flow 
still persists in the deep veins and in normal larger superficial veins, which 
have less collapsible walls. This difference between the volumes contained 
in floppy superficial varicose veins and the volumes contained in normal 
surface veins and deep veins may be exploited to cause damage that is 
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almost perfectly localized to superficial varices. If an elevated, empty 
varicose vessel is perfused with a concentration of sclerosant so low that 
even without dilution it is just barely sufficient to cause endothelial injury, 
then any further dilution will reduce the concentration below the threshold of 
injury. Because larger superficial vessels and deep vessels continue to carry 
a volume of blood in the leg-up position, any sclerosant passing into these 
vessels will immediately be diluted to a safe and noninjurious concentration, 
sparing the endothelium of vessels that we wish to preserve. Injection of this 
'threshold' concentration directly into a perforating vein (or even directly 
into a deep vein) will not cause any deep vein injury.  
The perfect sclerosant 
 The best imaginable sclerosant would have no systemic toxicity. It 
would be effective only above some threshold concentration, so that its 
effects could be precisely localized through dilution. It would require a long 
period of contact to be effective, so that it would be relatively more effective 
in areas of stasis and relatively safer in the deep veins where there is high 
flow. It would be non-allergenic. It would be strong enough to sclerose even 
the largest vessels, yet it would produce no local tissue injury if 
extravasated. It would not cause staining or scarring. It would not cause 
telangiectatic matting. It would be perfectly soluble in normal saline. It 
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would be painless upon injection. It would be inexpensive. It would be 
approved by the United States Food and Drug Administration.  
 No currently available sclerosant possesses all of the attributes of the 
perfect sclerosing agent. All currently available sclerosants fall short in one 
way or another, yet the variety of available agents is such that virtually every 
situation in which sclerotherapy is indicated can be safely and effectively 
handled by one or another of the available sclerosants, used alone or in 
combination.  
TYPES OF SCLEROSANTS : 
(I) DETERGENTS 
 These are fatty acids and fatty alcohols. Detergent sclerosants work by 
a mechanism known as protein theft denaturation, in which an aggregation 
of detergent molecules forms a lipid bilayer in the form of a sheet, a 
cylinder, or a micelle, which then disrupts the cell surface membrane and 
may steal away essential proteins from the cell membrane surface. Unlike 
many other agents, the detergent sclerosants do not cause hemolysis, nor do 
they provoke direct intravascular coagulation.  
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Determinants of activity of detergent solutions [18] 
(a) Concentration 
 At low concentrations, most detergent molecules are individually 
dissolved in solution, and there are very few micellar aggregates. When the 
concentration reaches some threshold (known as the critical micellar 
concentration, or CMC) nearly all further detergent molecules added to the 
solution will enter into micelles. Micelles can cause protein theft 
denaturation, but individual detergent molecules have no toxicity to the 
vascular endothelium, thus for each detergent sclerosant, there is some 
threshold concentration below which the agent causes no injury. This 
physical property means that detergent sclerosants offer significant benefits 
over most of the agents previously used, because they are potent agents that 
nonetheless have a clear-cut threshold below which they have absolutely no 
injurious effect on venous endothelium.  
(b) Temperature 
 The solubility of detergents is inversely temperature dependent. 
Because of the highly polar nature of water, and the entropic dependence of 
the hydrophobic effect, detergent molecules are much more soluble in cold 
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solutions than in hot ones. This effect is easily seen in everyday life: 
dishwashing detergent produces a large amount of persistent foam in warm 
water, while cold water rinses away the soapy foam easily. The solubility of 
sclerosing agents such as polidocanol is likewise much higher in cold 
solutions, and because single dissolved molecules are ineffective, the 
strength of the sclerosing effect is higher at warmer temperatures.  
(c) Mixing 
 Detergent micellar formation can reach a maximum level based upon 
the temperature and upon the concentration of the detergent in solution. 
Micellar formation is a steric process, however, and the geometry of macro 
assemblages often prevents maximal micellar formation. The surface area of 
lipid bilayer structures such as sheets, cylinders, and micelles is maximized 
when the solution is shaken to produce foam. Because it is the surface of 
these structures that causes protein theft denaturation, a solution that has 
been shaken will be a more effective sclerosant than one that has not. 
Unfortunately, foamy bubbles that are injected into spider veins or varicose 
veins can pass through a patent foramen ovale to lodge in the ocular and 
cerebral circulation, where they have produced temporary ischemic attacks 
with temporary blindness and other central nervous system effects.  
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Currently available detergent agents 
 1) Sodium morrhuate 
 2) Ethanolamine oleate 
 3) Sodium tetradecyl sulfate (Sodium 1-isobutyl-4-ethyloctyl 
sulfate) a synthetic long chain fatty acid that has seen extensive industrial 
use as a synthetic surfactant (soap). It is sold for medical use as a solution of 
up to 3% concentration with 2% benzoyl alcohol used as a stabilant. It is 
effective as a venous sclerosing agent in concentrations from 0.1% to 3%. 
The principal clinical problems with the drug are a tendency to cause 
hyperpigmentation in up to 30% of patients, a significant incidence of 
epidermal necrosis upon extravasation, and occasional cases of anaphylaxis.  
 4) Polidocanol (hydroxy-polyethoxy-dodecane) is a synthetic long-
chain fatty alcohol  
(II) HYPERTONIC AND IONIC SOLUTIONS 
 Strong solutions of hypertonic saline and other salt solutions are part 
of a class of solutions that are often referred to as osmotic sclerosants. These 
solutions have long been regarded as causing endothelial death by osmotic 
cellular dehydration. Although it is true that osmotic dehydration at the point 
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of injection is sufficient to rupture red blood cells and to dehydrate some 
nearby endothelial cells, the evidence suggests that these sclerosants are 
effective even after dilution has reduced the osmotic gradient far too low to 
account for the effects seen. Thermodynamic and physical chemical 
calculations suggest that these and other strong ionic solutions probably 
work by causing conformational denaturation of cell membrane proteins in 
situ. Like the detergents, they can be diluted to the point where they have no 
further cellular toxicity.  
 1) Hypertonic saline 
 2) Sclerodex  
Sclerodex is a mixture of 25% dextrose and 10% sodium chloride, with a 
small quantity of phenethyl alcohol.  
 3) Polyiodinated iodine 
(III) CELLULAR TOXINS 
 Other chemical sclerosants exist that probably act by a direct or 
indirect chemical toxicity to endothelial cells: by poisoning some aspect of 
cellular activity that is necessary for endothelial cell survival. Such agents 
are less useful to the extent that they also poison other bodily cells. They 
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also lack another of the key attributes of a good sclerosant: they remain toxic 
to some degree even after extreme dilution, so that there is no real threshold 
below which injury will not occur.  
 
 FOAM SCLEROTHERAPY 
 
 In foam sclerotherapy, the sclerosant is mixed with air or 
physiological gases. Foamed sclerosant blocks flow of blood into and out of 
the treated site and hence avoids dilution of the drug. Foam sclerotherapy is 
more efficacious than the direct injection of the sclerosants [3]. Air in the 
foam prolongs the contact of the agent with the endothelium. Maximum 
sclerosant action can be obtained at lesser concentration and quantity. 
Foamed agent exerts its effect at microcirculation, which is inaccessible to 
other procedures. 
INDICATIONS FOR SCLEROTHERAPY : 
• Varicose veins 
• Telangiestasias 
• Hemangiomas 
• Lymphangiomas 
• Pyogenic granulomas 
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 Veins of any size from small venous telangiectasias to large 
varicose veins and at any size from the face and scalp to the foot and ankle 
can be permanently eradicated by sclerotherapy. In case of incompetent 
venous junctions or incompetent perorating veins communicating with the 
varicose vein, interruption of these points of reflux (e.g. surgical ligation) 
and division should be considered before sclerotherapy. Hence sclerotherapy 
is effective in eradicating a segment of an axial vein, but unlike ligation and 
division, it cannot reliably target a finite point (e.g. saphenofemoral or 
saphenopopliteal junction, or a short segment of a perforating vein) without 
also infusing sclerosant into the deep venous system. In addition to the 
cosmetic purposes sclerotherapy serves, it is also performed to treat the 
soreness, aching, muscle fatigue, and leg cramps that often accompany 
small- or middle-sized varicose veins in the legs. 
CONTRAINDICATIONS FOR SCLEROTHERAPY : 
• Allergy to the sclerosants 
• Pregnancy 
• Lactation 
• Deep vein thrombosis 
• Congenital and acquired coagulation abnormalities  
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MATERIALS AND METHODS 
 
Study type : Prospective non-randomized interventional study 
 
Study population :  40  patients of both sex; age group : 15 to 65 years 
            { 28 with varicose veins with complications 
                                 10 with hemangioma  
                                  2 with lymphangioma } 
           
Study period : January 2009 to September 2010 (18 months) 
      First 6 months : Interventional period 
      Next 12 months : follow-up period 
 
Place of study : Department of Dermatology, 
        Govt. Stanley Medical College, Chennai. 
 
The patients chosen for the study, were from the general pool 
attending the Dermatology out patient department. Initially, 70 patients with 
varicose veins who came with complaints of pain, itching, edema, 
discolouration, dilated veins over legs; 15 with hemangioma presenting with 
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swelling and 2 with lymphangioma were subjected to the pre-sclerotherapy 
consultation, assessment and investigations as given below. Out of them, 28 
patients with varicose veins (legs), 10 patients with hemangioma (tongue, 
gluteal region, hand, trunk of size varying from a minimum of 3 x 2cm to a 
maximum of 12x8cm) and 2 with lymphangioma (posterior one third of 
tongue and gluteal region), who were enrolled for the study, according to the 
inclusion and exclusion criteria. The mean age group was 32.7 years (15 – 
65 years) of both sexes.  
 
PRE – SCLEROTHERAPY CONSULTATION : 
 
¾ Thorough explanation of the procedure, course of treatment and potential 
adverse effects were explained 
¾ Informed and written consent was obtained 
¾ A thorough history regarding the onset, duration, etiological factors, 
complications, other systemic illnesses, hypersensitivity to sclerosants, 
pregnancy, lactation and past history regarding any modes of treatment 
for the condition was taken (ANNEXURE - I) 
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 PRE – SCLEROTHERAPY ASSESSMENT :   
  
 A meticulous clinical examination as given in ANNEXURE – I was 
done with the following tests for varicose veins : 
- Tourniquet test 
- Brodie-Trendelenberg test 
- Fegan’s test 
- Pratt’s test 
- Perthes test 
- Homan’s sign 
- Moses sign 
 - Schwartz’s test 
 
Investigations : 
  
In all patients with varicose veins, Doppler ultra sonogram of venous 
and arterial systems of both lower limbs, ultra sonogram of abdomen and 
pelvis and coagulation profile was done. In patients with hemangiomas and 
lymphangiomas, contrast enhanced CT scan, MRI and coagulation profiles 
were done (as required).  
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 With the history, clinical examination and the aid of laboratory 
investigations, patients were selected according to the inclusion and 
exclusion criteria. 
Inclusion criteria : 
1.  Willing to be enrolled for  
     the complete study period 
2. superficial varicosities with no junctional refluxes 
3. reticular veins 
4. patients unfit for surgical  procedure 
5. recurrence after surgery  
6. post surgical ligation of major refluxes 
 
Exclusion criteria : 
1. deep venous thrombosis 
2. veins with reflux from the greater or lesser saphenous junction    
      per se  
3.  perforator incompetence 
4.  coagulation abnormalities 
5.  allergy / hypersensitivity to the drug  
6.   pregnancy 
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7.   lactation 
8.  on oral contraceptive pill or hormone replacement therapy 
 
PROCEDURE : 
 
Requirements (Figure 1) : 
 
¾ Sclerosing agent – sodium tetradecyl sulphate (3%) EDA and FDA 
approved detergent sclerosant 
¾ 0.9% saline as diluent 
¾ 5 ml syringes 
¾ Scalp vein set 
¾ Sterile bowl for sclerosant 
¾ Gloves 
¾ Alcohol pads 
¾ Gauze 
¾ Elasto-crepe bandage roll 
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Figure 1 - Sclerotherapy supply tray 
 
 
 
 
 
 
 
 
FOAM SCLEROTHERAPY TECHNIQUE :  
 
¾ Positioning of patient : 
Patient should be recumbent [18] during the procedure, for comfort and to 
promote venous emptying. 
 
¾ Visualization of the vein : 
The skin where the injection is to be given is wiped with surgical spirit to 
remove oil, dirt and for easy visualization of the vein (as wetting of the skin 
lowers its refractive index) 
 
¾ Preparation of the foam sclerosant :  
1. Sodium tetradecyl sulphate 3% (STS), which is an EDA and 
FDA [19] approved detergent sclerosant is diluted with normal 
saline to get 0.5 – 2% solution.  
2. Quantity per session and concentration used were based on the 
diameter of the vessel, size of the hemangioma and the response 
to treatment. Quantity used by us per session was 1 – 3 ml.  
3. Concentration of the sclerosant :                                             
The concentration of injected sclerosant is determined mainly 
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by the mural thickness of the vein, which is directly correlated 
with the lumen diameter as given in table I. The greater the vein 
diameter, the greater the concentration of sclerosant that will be 
needed. Injection of  too low a concentration will be inadequate 
to produce full mural denaturation. Injection of too high a 
concentration can produce extra vascular tissue devitalisation. 
TABLE - I  
 
Diameter of the vessel 
 
Concentration of sclerosant 
< 0.5mm 0.1 % 
0.6 – 1.5mm 0.25 % 
1.5 -  4mm 0.5 – 1 % 
4 -6 mm 1 – 2 % 
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Calculation of dilution volumes for sclerosants is done using the 
formula : 
Cf = Ci [ Vs / (Vs + Vd)] 
 
Cf – final concentration (in %) of the sclerosant  
Ci - initial concentration (in %) of the sclerosant 
Vs – initial volume (in ml) of undiluted sclerosant 
Vd – diluent volume (in ml) of 0.9% saline solution 
 
 For example, to prepare 0.5% solution of STS, using 1 ml of 3% STS, 
the volume of 0.9% normal saline to be added is calculated using the above 
formula : 
 
Cf = Ci [ Vs / (Vs + Vd)] 
0.5 = [3] [ 1 / ( 1 + Vd)] 
0.5 / 3 = 1 / ( 1 + Vd) 
0.5 + 0.5 Vd  = 3 
Vd = 5 ml 
Hence 5 ml of 0.9% normal saline is needed to make 3% STS (1 ml) to 0.5% 
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¾ Foaming of the sclerosant : 
 Foaming is done by ‘Tessari’ method [20], in which a 5 ml syringe is 
filled with room air, another syringe is filled with 1 ml of the diluted 
sclerosant and the two syringes are connected to a 3 way stop cock (Figure 
2). Foaming is done by to and fro movement of both the syringes (Figure 3).  
 
¾ Injection of the sclerosant : 
1. The cannula of the needle is introduced into the vein such that it 
enters parallel to the vessel’s course. The bevelled edge is 
positioned to face upwards (towards the skin surface), so that 
even if extravasation occurs, it will be superficial and hence 
easily visualized as a bleb, and not deposited deeper.  
2. In case of varicose veins, cannulation is done from the proximal 
end (Figure 4) and hemangiomas are cannulated at the base [21] 
(Figure 5). 
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Foaming of the sclerosant done by ‘Tessari’ method 
Figure 2 
 
Figure 3 
 
 Figure 4 – cannulation of varicose vein 
 
 
Figure 5 – cannulation of hemangioma 
      
3. The vein is pierced and after confirming the intraluminal 
position of the cannula, the limb is elevated to 45o [18] to further 
empty the vein and the diluted sclerosant is slowly introduced 
into the vein. 
4. Once extravasation or high injection pressure is experienced, 
further injection is stopped. 
5. Immediately after the procedure, a circumferential compression 
bandaging [22] is done using elasto-crepe bandage (Figure 6). 
 
 POST PROCEDURE ADVISES: 
 
¾ To wear compression stockings at all times, day and night, at least for 2 
weeks.  
¾ To keep their legs elevated 
¾ To carry out normal daily activities  
¾ To avoid strenuous exercise 
¾ To avoid standing still for long periods 
¾ Bed rest was not recommended. 
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Figure 6 – Post sclerotherapy compression bandaging 
 
FOLLOW UP : 
  
 Follow up was done at every 2 weeks interval assessing the fibrosis of 
the vessels, reduction in size of the hemangioma and local or systemic 
complications (if any). Procedure was repeated at an interval of 2 weeks 
depending upon the response which was judged clinically. Doppler ultra 
sonogram was repeated at the end of 3rd, 6th, 12th,18th months. 
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RESULTS 
 
 
 
 
 RESULTS 
 
Total no. of patients in the study group :  
Male                                                       : 30 
Female                                                   : 10 
 
Out of 28 patients with varicose veins –3 patients presented with pain 
over the dilated veins, 3 with swelling of feet, 2 with itching, 4 with 
discolouration of legs, 4 with leg ulcer, 12 with stasis dermatitis. 
 
TABLE  1 – SYMPTOM-WISE DISTRIBUTION OF PATIENTS 
 
SYMPTOM 
 
NO. OF PATIENTS 
Pain 3 
Swelling of feet 3 
Itching 2 
Discolouration 4 
Leg ulcer 4 
Stasis dermatitis 12 
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TABLE  2 - VESSEL CLASSIFICATION [57]   
 
VESSEL 
TYPE 
DEFINITION 
VESSEL 
DIAMETER 
(mm) 
NO.OF 
PATIENTS 
1 Spider veins 0.1 – 1.0 - 
1-A Telangiectatic matting <0.2 1 
1-B 
Telangiectasia communicating 
with saphenous system 
0.2 – 1.0 1 
2 
Mixed telangiectatic/varicose 
veins 
1.0 – 6.0 4 
3 
Non-saphenous varicosities 
(reticular veins) 
2.0 – 8.0 3 
4 Saphenous varicose veins >8.0 19 
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TABLE  1 – SYMPTOM-WISE DISTRIBURION OF PATIENTS 
43%
11%
11%
7%
14%
14%
pain
swelling of feet
itching
discolouration
leg ulcer
stasis eczema
 
TABLE  3 - PERCENTAGE RESPONSE OF SYMPTOMS AFTER 
TREATMENT  
 
 
 
SYMPTOM 
NO. OF 
PATIENTS 
WITH THE 
SYMPTOM 
BEFORE 
TREATMENT 
NO. OF 
PATIENTS 
WITH THE 
SYMPTOM 
AFTER 
TREATMENT 
PERCENTAGE 
IMPROVED 
(%) 
Pain 3 1 66.7 
Swelling 3 1 66.7 
Itching 2 1 50 
Discolouration 4 4 0 
Leg ulcer 4 2 50 
Stasis eczema 12 8 66.7 
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CHART (TABLE  3) - RESPONSE OF SYMPTOMS AFTER TREATMENT : 
3 3
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a
After treatment Before treatment
 
No of 
patients 
At the end of 3 months (completion of 2 sittings):  
 4 patients with varicose veins, 2 patients with hemangioma showed 
complete resolution; near complete resolution was seen in 16 cases with 
varicose veins, 6 with hemangioma and 1 with lymphangioma; partial 
resolution was seen in 8 with varicose veins, 2 with hemangioma and 1 with 
lymphangioma. 
 
At the end of  6 months (completion of 5 sittings): 
 23 patients with varicose veins, 6 with hemangioma and 1 with 
lymphangioma showed complete resolution; near complete resolution was 
seen in 3 cases with varicose veins, 4 with hemangioma and 1 patient with 
lymphangioma; partial resolution was seen in 2 patients with varicose veins. 
 
At the end of 12th month : 
 27 patients with varicose veins, 7 with hemangioma and 1 with 
lymphangioma showed complete resolution; near complete resolution was 
seen in 1 patient with varicose vein, 3 patients with hemangioma and 1 
patient with lymphangioma. 
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At the end of 18th month : 
 Out of 28 patients with varicose veins who showed complete 
resolution, 3 had recurrence, 7 with hemangioma and 1 with lymphangioma 
showed complete resolution; near complete resolution was seen in 3 patients 
with hemangioma and 1 patient with lymphangioma. (Table 4) 
 
CRITERIA FOR RESOLUTION : 
  
COMPLETE RESOLUTION :  
¾ varicose veins – complete obliteration of vein with no flow 
¾ hemangioma and lymphangioma – complete absence of flow in the 
vessels (Doppler) 
 
NEAR COMPLETE RESOLUTION : 
¾ varicose veins – decrease in luminal diameter more than 75% of   
             initial diameter (by Doppler) 
¾ hemangioma and lymphangioma - decrease in size more than 75% of 
initial (clinical) and/ or decrease in flow more than 75% of initial 
(Doppler) 
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PARTIAL RESOLUTION :  
¾ varicose veins – decrease in luminal diameter less than 75% of  initial 
(Doppler)    
¾ hemangioma and lymphangioma - decrease in size less than 75% of initial 
(clinical) and/ or decrease in flow less than 75% of initial (Doppler) 
 
RECURRENCE :  
Varicose veins, hemangioma &  
lymphangioma   
 
 
 
 
 
 
- Detection of flow in vessels which had 
attained  
 
   complete resolution 
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Table 4 : Response to treatment during follow-up 
 
RESPONSE VARICOSE VEINS 
(months) 
HEMANGIOMA 
(months) 
 
LYMPHANGIOMA 
(months) 
 
3 6 
 
12 
 
18 3 6 12 18 3 6 12 18 
Complete 4 23 27 25 2 6 7 7 - 1 1 1 
Near complete 16 3 1 - 6 4 3 3 1 1 1 1 
Partial 8 2 - - 2 - - - 1 - - - 
Recurrence - - - 3 - - - - - - - - 
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                     At the end of 3 months ( completion of 2 sittings) : 
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At the end of 12th month : 
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At the end of 18th month : 
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Figure 6-A : Localized varicose vein Rt. Leg –Before treatment  
 
 
       
 
 
 
           Figure 6-B : After 2 sittings of sclerotherapy  
 
 
          
        Figure 7-A : Varicosity of great saphenous vein Lt. Leg 
                    – Before treatment 
 
 
 
 
 
 
 
        Figure 7-B : After 4 sittings of sclerotherapy  
 
 
 
 
 
 
 
 
 Figure 8-A : Localized varicosity of Lt. great saphenous vein  
 
 
 
 
 
       Figure 8-B : After 4 sittings of sclerotherapy  
 
 
 
 
 
 
 
 
Figure 9-A : Lt. leg varicose vein with stasis eczema  
                      and venous ulcer  
 
 
 
 
 
 
          Figure 9-B : After 5 sittings of sclerotherapy 
                   – healing of stasis eczema & ulcer  
 
 
 
 
  Figure 10-A : Lt. leg varicose vein - before treatment  
 
 
       Figure 10-B : After 3 sittings of sclerotherapy  
 
 
        Figure10-C : After 5 sittings of sclerotherapy  
 
 
 
 
 
Figure 11-A : Varicosity of small saphenous vein Lt. leg  
 
 
 
 
 
 
 
       Figure 11-B : After 3 sittings of sclerotherapy  
 
 
 
 
 
 
 
Figure 12-A :Localized varicosity of Rt. Great saphenous vein  
 
 
 
 
 
 
 
 
 
              Figure 12-B : After 5 sittings of sclerotherapy  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13-A : Lymphangioma – posterior 1/3rd of tongue  
 
 
 
 
 
       Figure 13-B : After 5 sittings of sclerotherapy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Figure 14-A : Hemangioma – tongue  
 
 
 
       Figure14-B : After 6 sittings of sclerotherapy  
 
 
 
         Figure 15-A : Hemangioma – gluteal region   
 
 
 
 
 
      Figure 15-B : After 6 sittings (partial resolution) 
    
 
 
 
 
Figure 16-A : Hemangioma Lt. hand 
 
 
 
 
 
 
 
       Figure 16-B : After 2 sittings of sclerotherapy  
 
 
 
 
INTERPRETATION OF RESULTS : 
 
 
The average no. of sittings required for complete resolution : 
¾ 4.2 sittings for varicose veins 
¾ 3.9 sittings for hemangiomas 
¾ 5.5 sittings for lymphangioma 
This in turn depends upon the diameter and length of the veins and the size 
of the hemangioma. 
 
 
COMPLICATIONS OBSERVED : 
 
¾ The following complication were noted during the study : 
 
COMPLICATION 
 
NO. OF PATIENTS 
Swelling of the treated limb 3 
Pain over the treated site 3 
Cutaneous ulceration           1 
Staining of skin at and around treated site           4 
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¾ No immediate complications like hypersensitivity reactions, were noted. 
¾ No serious complications like deep vein thrombosis or pulmonary edema 
were noted. 
¾ Pain and swelling after treatment persisted for 1-2 weeks and subsided 
with oral analgesics. 
¾ Post-sclerotherapy staining (Figure 17) gradually faded in 3 patients over 
a period of 6 – 10 months and was persistent in one patient even at the end 
of 18 months 
¾ The cutaneous ulceration (Figure 18) which had occurred secondary to 
extravasation of the sclerosant healed in 2 months with conservative 
management (Figure 18A). 
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Figure 17 : Post-sclerotherapy staining of skin  
along the course of the vein                
   
 
Figure 18-A : Cutaneous ulceration – due to extravasation  
   
 
 
         Figure 18-B : Healing of the ulcer  
 
    
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 Varicose veins and telangiectatic leg veins have plagued both men and 
woman since humans first assumed an upright posture.  
 According to Tollins SH [23], varicose veins occur more commonly in 
women than men with a ratio 4:1 to 5:1, whereas in this study we have found 
an increased incidence in men 3.7:1 (male : female). 
 Though there are various treatment options available for varicose 
veins as discussed above, veins less than 5mm in diameter and those not 
associated with junctional refluxes or perforator incompetence can be treated 
by non-surgical methods.  
 Sclerotherapy is the "gold standard" and is preferred over laser for 
eliminating large spider veins (telangiectasiae) and smaller varicose leg 
veins [24]. The foam sclerosant drug is more efficacious than the liquid one in 
causing sclerosis, for it does not mix with the blood in the vessel and in fact 
displaces it, thus avoiding dilution of the drug and causing maximal 
sclerosant action. It is therefore useful for longer and larger veins [25]. 
Experts in foam sclerotherapy have created “tooth paste” like thick foam for 
their injections, which has revolutionized the non-surgical treatment of 
varicose veins [26]. 
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 A study by Kanter and Thibault in 1996 reported a 76% success rate 
at 24 months in treating saphenofemoral junction and great saphenous vein 
incompetence with STS 3% solution [27].In our study 89.2% success rate was 
noted. 70% of patients with hemangioma and 50% with lymphangioma 
showed complete resolution over a period of 18 months. 
  Padbury and Benveniste [28] found that ultrasound guided 
sclerotherapy was effective in controlling reflux in the small saphenous vein. 
Barrett et al found that microfoam ultrasound guided sclerotherapy was 
"effective in treating all sizes of varicose veins with high patient satisfaction 
and improvement in quality of life"[25]. 
 A Cochrane Collaboration review of the medical literature concluded 
that "the evidence supports the current place of sclerotherapy in modern 
clinical practice, which is usually limited to treatment of recurrent varicose 
veins following surgery and thread veins."[29] A second Cochrane 
Collaboration review comparing surgery to sclerotherapy concluded that 
sclerotherapy has greater benefits than surgery in the short term but surgery 
has greater benefits in the longer term. Sclerotherapy was better than surgery 
in terms of treatment success, complication rate and cost at one year, but 
59 
surgery was better after five years. However, the evidence was not of very 
good quality and more research is needed.[30] 
 The work of Cabrera [31] and Monfreaux in utilizing foam 
sclerotherapy along with Tessari's "3-way tap method" [20] of foam 
production further revolutionized the treatment of larger varicose veins with 
sclerotherapy 
 George Fegan in the 1960s reported treating over 13,000 patients with 
sclerotherapy, significantly advancing the technique by focusing on fibrosis 
of the vein rather than thrombosis, concentrating on controlling significant 
points of reflux, and emphasizing the importance of compression of the 
treated leg [32]. 
 The degree of compression necessary after sclerotherapy directly 
correlates with the maximal intravascular pressure that the vein sustains. 
External compression must exceed the maximal intravascular pressure to 
prevent any blood return into the lumen of denatured vein. A class 2 gradient 
compression hosiery is advocated in many studies with a pressure of 30 to 
40mm Hg. 
 Compression serves atleast five main purposes: 
¾ If adequate, results in direct apposition of the treated vein walls to 
produce a more effective fibrosis [33]. 
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¾ Decreases the extent of thrombus formation [34]. 
¾ Decreases the incidence of post-sclerotherapy pigmentation [35]. 
¾ Prevents telangiectatic matting [36].  
¾ Improves function of calf muscle pump [37]. 
 
ADVERSE SEQUELAE & COMPLICATIONS OF SCLEROTHERAPY 
[53], [ 54],  [55] 
¾ Temporary hyperpigmentation 
¾ Temporary swelling 
¾ Telangiectatic matting 
¾ Pain 
¾ Localized urticaria 
¾ Tape / compression blister 
¾ Tape compression folliculitis 
¾ Cutaneous necrosis 
¾ Systemic allergic reaction 
¾ Thrombophlebitis 
¾ Arterial injection 
¾ Pulmonary embolus 
¾ Stroke 
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HYPERSENSITIVITY REACTION : 
  Immediate hypersensitivity to sclerosing agent or its 
preservative could appear as a rare phenomenon[38], which can be treated 
with subcutaneous epinephrine (0.5ml of epinephrine 1:1000) 
 
VASOVAGAL REACTION : 
 Some patients may develop a vasovagal reaction with a sudden drop 
in blood pressure. It is quite rare with the recumbent position which we 
follow during sclerotherapy. If the decrease in blood pressure is significant, 
and sudden, a transient loss of consciousness occurs due to inadequate 
cerebral perfusion. The treatment involves foot end elevation and for a 
mo0re severe reaction intravenous administration of atropine 0.5mg is given. 
If no response is observed, a second dose is given. 
 
POST-SCLEROTHERAPY HYPERPIGMENTATION : 
 A linear pigmentation along the course of the treated vein can occur 
within a few weeks. This is attributed to the hemosiderin that is formed out 
of hemoglobin that has remained in the vein’s lumen. It is a part of the 
resolution process and the patient is to be reassured. This adverse sequel has 
been described in 30% of the patients treated with sodium – 
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-tetradecylsulphate [ 39] Persistent thrombi are thought to produce a subacute 
perivenulitis that can persist for months. The perivenulitis favours 
extravasation of RBCs through  endothelium or by increasing the 
permeability of injected endothelium and possibly intratissue fixation of 
hemosiderin [40], [41]. According to Mitchel. P. Goldman, draining all the 
thrombi between 2 and 4 weeks of sclerotherapy by puncturing using  23 
gauge needle, followed by gentle massage is important in preventing 
pigmentation. As observed by Carlin MC, Ratz JL the pigmentation lasts 
from 6 to 24 months [42], which is almost consistent with the results observed 
in our study (6 to 10 months). 
 Ecchymosis at and around the injection site may occur due to 
actinically damaged senescent skin, or due to intake of anticoagulant drugs 
 
TELANGIECTATIC CAPILLARY MATTING : 
 The appearance of capillary telangiectasias – thread-like, red vessels 
less than 0.2mm in diameter at and around the treated veins is reported, upto 
18%[ 43]  . It is more likely to occur if a higher than necessary concentration 
of sclerosant is used or if injection pressure is high enough to promote 
retrograde flow of sclerosant. 
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INTRAVASCULAR THROMBOSIS : 
 Treatment associated superficial thrombophlebitis occurs, as 
immediately after sclerotherapy some amount of blood returns into the 
lumen even when appropriate compression has been applied. This column of 
blood gets thrombosed and results in superficial thrombophlebitis. This 
usually resolves uneventfully within a few weeks or months. The chances of 
deep vein thrombosis is purely theoretical, as any properly administered 
sclerosant that has entered the deep venous system will be diluted to an 
extent as to render it impotent to cause a deep venous mural thrombosis. 
Post-sclerotherpy compression, initially described by Sigg [44] and Orbach [45] 
in 1950s and Fegan in 1960 [34], eliminates thrombophlebitic reaction and 
substitutes a ‘sclerophlebitis’ with the production of a firm fibrous cord [46]. 
 
CUTANEOUS DEVITALIZATION : 
 An excessive inflammation that develops unexpectedly at a treatment 
site or a retrograde flow of sclerosant from the treated vein into more 
proximal capillaries or arterioles at the time of infusion or due to 
extravasation of the sclerosants [58], [59] . The extravasated sclerosant 
manifests immediately as a bleb or wheal. At this stage, dessication of the 
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wound can be prevented by an occlusive ointment. If ulcer develops oral 
antibiotics and wound dressing along with compression, promotes healing.  
 
ARTERIAL INJECTION : 
The most feared complication in sclerotherapy is inadvertent injection of the 
sclerosant into an artery, though it is very rare [48], [49]. The most common 
location for this is in the medial malleoli region [50]. The patient will usually, 
but not always, complains of immediate pain. Cutaneous blanching of the 
injected site occurs along with loss of pulse and progressive cyanosis of the 
injected area. This complication is a true ‘sclerotherapy emergency’ and 
should be immediately treated with 1 ml of procaine 3% as it will complex 
with STS and renders it inactivate. Immediate heparinization for 6 days with 
administration of IV dextran 10%, 500ml per day for 3 days is 
recommended. IV streptokinase may be considered if there are no 
contraindications. Finally oral prazosin, hydralazine or nifedipine should be 
considered for 30 days 
 
PULMONARY EMBOLISM AND STOKE : 
Fortunately, pulmonary embolism is very rare to occur (1in 40,000). Risk of 
emboli may be increased by use of estrogens [51]. Most cases have occurred 
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with high injection volume of about 12ml at a given site. Therefore to 
minimize this potentially fatal complication, sclerosant quantity should be 
limited to 0.5 to 1 ml per injection site to prevent leakage of sclerosant into 
the deep venous system. Rapid compression bandaging of the injection site 
followed by immediate ambulation or calf movement with frequent 
ambulation thereafter promotes rapid dilution of sclerosant from the injected 
site. 
¾ The complications observed in this study were post-sclerotherapy 
pigmentation (4), edema and pain over injected site(3) and cutaneous 
ulceration (1)  
¾ Though the above described complications have been reported in various 
studies, we never experienced any of the serious complications.  
 
DURATION OF VEIN DISAPPEARANCE ; 
 The duration non resorption of veins depends upon various factors 
like vein size, volume of blood that has re-entered the lumen after 
sclerotherapy. Proper compression attempts are required to minimize the 
volume of blood in the vein. According to Orbach EJ, patients should be 
examined 2 weeks after injection so that any area of thrombosis can be 
evacuated early [52]. Each individual area should not be treated sooner than 6 
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to 8 weeks after injection to allow for adequate healing of the endothelium 
between treatments. 
 
RECURRENCE AFTER SCLEROTHERAPY : 
 A great disadvantage of foam injection sclerotherapy is the significant 
chance of recanalisation of the treated vessels, resulting in recurrence of 
superficial venous incompetence. Although recurrence is a significant 
shortcoming of any kind of sclerotherapy, including foam sclerotherapy, it 
should be remembered that, unlike surgery, foam sclerotherapy is a 
minimally invasive technique that can be repeated without any real increase 
in the risks or complexity of the procedure. 
 
POST-SCLEROTHERAPY ACTIVITY : 
 Immediately after sclerotherapy, patient may participate in all day to 
day activities.  
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CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
Following were the conclusions derived from this study 
¾ Sclerotherapy is a potentially valuable method of treatment for vascular 
and lymphatic malformations 
¾ Foam sclerotherapy causes maximal sclerosant action at lesser 
concentration and quantity 
¾ The effect is exerted at microcirculation which cannot be achieved 
through any other procedures. 
¾  This study demonstrates a complete resolution rate of 89.2% for varicose 
veins in an average of 4.2 sittings, 70% for hemangiomas – average of 3.9 
sittings and 50% in case of lymphangiomas in 5.5 sittings (average), over 
a period of 18 months. 
¾ The healing of stasis dermatitis (66.7%) and venous ulcers (50%) were 
found to be accelerated following foam sclerotherapy. 
¾ Though a recurrence rate of 10.7% was noted in patients with varicose 
veins, foam sclerotherapy is a minimally invasive technique that can be 
repeated without any real increase in the risks or complexity of the 
procedure. 
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¾ Only minor adverse effects like postsclerotherapy pigmentation , 
cutaneous devitalisation (1 patient) were noted. No major complications 
like anaphylaxis, pulmonary embolism or stroke were observed. 
¾ Hence foam sclerotherapy is a simple, safer, feasible, affordable in-office 
procedure which can be performed without hospitalization or anaesthesia. 
¾ It allows the patient, a rapid return to normal daily activity 
¾ Furthermore it is cheap in comparison to almost all of the other methods 
available today.  
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     PROFORMA 
 
 
 
 
Name    Age    Sex 
 
Skin O.P No : 
 
Occupation : 
 
Address : 
 
Per capita income : 
 
Presenting complaints : 
 
H/o present illness : 
  
onset 
duration 
course 
H/o associated symptoms 
H/o leg ulcers 
H/o predisposing factors 
H/o aggravating / relieving factors 
H/o abdominal distension/ mass/ pain 
H/o other systemic disturbances  
 
Past history : 
 
 H/o any surgeries for varicose veins / hemangiomas in the past 
 H/o any abdominal surgeries 
 
Family history : 
 
Personal history : 
 
 Diet : 
 Sleep : 
 Appetite : 
 Bowel & bladder  habits : 
 Habits : smoking / alcoholism 
 
Menstrual history (in females): 
 
 Menarche/menopause; cycles; flow 
 
Obstetric history (in females): 
  
 H/o pregnancy / lactation 
 H/o intake of OCPs 
 
Treatment history : 
  
H/o previous treatment / surgeries 
H/o allergy to sclerosants 
General Physical Examination : 
 
 Consciousness; orientation  
 
Built & nourishment 
  
Febrile/afebrile 
 
Pallor / cyanosis / clubbing / icterus / lymphadenopathy / pedal edema 
 
Pulse rate :    Peripheral pules : 
 
Blood pressure : 
 
Respiratory rate ; 
 
Temperature : 
 
 
Systemic Examination : 
 
 Cardiovascular system : 
 
 Respiratory system : 
 
 Abdomen (including genital and per rectal examination): 
 
 Central nervous system : 
 
Local Examination : 
 
I Hemangiomas: 
 
Inspection:  
 
- Number ; size ; site ; shape ; surface ; skin around the swelling ;       
cough impulse 
 
Palpation : 
 
- extent ; warmth ; tenderness ; pulsation/thrill ; compressibility;     
cough impulse ; girth of the limb 
 
Auscultation : 
 
 - bruit  +/- 
  
 
II Varicose veins : 
 
Inspection : 
 
- site & extent of varicosity 
- surrounding skin     
Palpation : 
 
- warmth 
- tenderness 
- pitting edema of leg 
CLINICAL TESTS: 
      
¾ Tourniquet test   
 A tourniquet is applied just below the level of the SFJ and the patient 
is then asked to stand. Rapid filling of the varicosities with the tourniquet 
still on suggests incompetent perforators below the level of the SFJ. If no 
filling is seen at this point, the tourniquet is released. Rapid filling of the 
varicosities at this stage suggests SFJ incompetence.  
¾  Brodie-Trendelenberg test  
 Similar to tourniquet with compression given at the saphenofemoral 
junction using thumb.  
¾ Fegan’s test  
 On standing, the site where the perforators enter the deep fascia 
bulges and this is marked. On lying down, button like depressions in the 
deep fascia are felt at the marked out points which confirms the site of 
perforators. 
¾  Pratt’s test  
 An Esmarch bandage is applied to the leg from below upwards with a 
tourniquet at the saphenofemoral junction. After the bandage is released, 
perforators are seen as ‘blow-outs’ 
 
 
¾  Perthes test  
 The affected limb is wrapped with elastic bandage, and the patient is 
asked to walk around and exercise. Development of severe pain indicates 
DVT. 
¾ Homan’s sign  
 Dorsiflexion of foot elicits pain in posterior calf.  
¾ Moses sign  
 Squeezing of posterior calf elicits pain.  
Percussion : 
¾  Schwartz’s test  
 This technique is useful in determining whether 2 venous segments 
are directly interconnected. With the patient in a standing position, a vein 
segment is percussed at one position while an examining hand feels for a 
"pulse wave" at another position 
 
 
 Auscultation : 
 
- Any continuous machinery murmur of AV fistula +/- 
 
Examination of ulcer (if any) 
 
Examination of skin changes (if any) 
 
 
 
DIAGNOSIS : 
 
 
 
INVESTIGATIONS : 
 
 
Hb%, TC, DC, ESR, Platelet 
  
Urine – albumin, sugar, deposits 
 
BT, CT 
 
Doppler ultrasonogram both limbs 
 
Ultrasonogram abdomen & pelvis 
 
CT scan (as required) 
 
MRI (as required) 
 
 
MASTER CHART – VARICOSE VEINS 
 
S.No NAME AGE SE
X 
SYMPTOM VESSEL 
TYPE 
BT CT STS 
CONC. 
(%) 
 
NO.OF 
SITTINGS 
SYMPTO
M AFTER 
TRT 
RESOLUTION 
1. MURALI 35 M Stasis eczema 4 2’10” 4’11” 1 4 Reduced Complete 
2. GOPALAN 45 M Pain 1A 3’12” 5’21” 1 5 Persistent Complete 
3. DAYALAN 38 M Discolouration 3 4’11” 4’9” 0.1 2 Persistent Complete 
4. VEERAN 55 M Stasis eczema 2 2’9” 4’14” 0.75 3 Persistent Complete 
5. SUMATHI 34 F Itching 4 2’14” 6’16” 1.5 5 Reduced Complete 
6. PANDIYAN 48 M Stasis eczema 4 2’6” 5’10” 2 4 Reduced Complete 
7. GODHANDAM 37 M Leg swelling 4 2’10” 4’16” 1 6 Reduced Complete 
8. LAKSHMI 38 F Leg ulcer 4 3’10” 6’12” 1.5 5 Healed Complete 
9. KANNAN 50 M Stasis eczema 4 2’8” 5’8” 0.25 2 Persistent Complete 
10. SIVARAMAN 32 M Leg ulcer 2 2’10” 4’30” 1 4 Reduced Complete 
11. PARAMASIVAM 42 M Stasis eczema 4 4’00” 7’11” 1.5 6 Reduced Complete 
12. SHANTHI 48 F Stasis eczema 4 2’13” 4’18” 1 4 Reduced Complete 
13. RIYAZ 53 M Stasis eczema 1B 2’8” 5’11” 1.5 5 Reduced Recurrence 
14. RAHIMA 35 F Pain 2 3’13” 4’10” 0.75 3 Reduced Complete 
15. RAMESH 44 M Stasis eczema 3 2’14” 4’15” 1.5 5 Reduced Complete 
16. SUBBAMMAL 36 F Discolouration 4 2’16” 6’14” 1 4 Persistent  Complete 
17. VELAN 40 M Itching 4 2’5” 5’10” 0.5 2 Reduced Complete 
18. SUBRAMANI 39 M Stasis eczema 4 2’10” 5’18” 1 6 Persistent Complete 
19. MANIKANDAN 43 M Stasis eczema 4 2’17” 4’40” 1.5 4 Reduced Complete 
20. GANDHI 33 M Leg ulcer 3 2’15” 5’6” 1 5 Persistent Complete 
21. ESWARAN 47 M Discolouration 4 3’10” 5’12” 1.5 6 Reduced Complete 
22. MADHIVANAN 37 M Pain 4 3’15” 6’11” 0.75 3 Reduced Complete 
23. RAJARAMAN 32 M Stasis eczema 2 3’30” 7’00” 0.5 2 Persistent Complete 
24. KUMAR 43 M Leg swelling 4 4’10” 4’11” 0.75 5 Reduced Recurrence 
25. PRAMILA 35 F Leg ulcer 4 3’12” 4’00” 0.75 3 Healed Complete 
26. SENTHIL 45 M Stasis eczema 4 5’10” 6’18” 1 4 Reduced Complete 
27. SARAVANAN 43 M Leg swelling 4 2’10” 4’11” 6 6 Reduced Complete 
28. IYYANAR 50 M Discolouration 4 3’20” 5’10” 1 4 Persistent Recurrence 
ABBREVIATIONS : BT – Bleeding time; CT –Clotting time; STS – Sodium tetradecyl sulphate; conc. - concentration 
MASTER CHART – HEMANGIOMA & LYMPHANGIOMA 
 
    
S.No NAME AGE SEX SITE BT CT 
STS 
CONC. 
(%) 
 
NO.OF 
SITTINGS RESOLUTION 
HEMANGIOMA 
1.  RAGHU 23 M Gluteal 3’10” 5’10” O.75 6 Near complete 
2.  SAVITHA 16 F Trunk 2’18” 6’18” O.75 4 Complete 
3.  JAYARAJ 19 M Tongue 2’10” 4’40” O.75 3 Complete 
4.  RAVI 24 M leg 4’20” 4’6” O.75 5 Near complete 
5.  JAGAN 20 M Forearm 2’13” 5’12” O.75 3 Complete 
6.  MARY 17 F Hand 2’8” 7’10” O.75 3 Complete 
7.  SATHISH 14 M Face 3’13” 3’18” O.75 2 Complete 
8.  JEBARAJ 30 M Trunk 4’10” 4’40” O.75 5 Near complete 
9.  SATHYA 27 F Tongue 2’8” 4’6” O.75 6 Complete 
10. HUSSAIN 31 M Hand 3’10” 3’12” O.75 2 Complete 
LYMPHANGIOMA 
1.  SELVI 14 F Tongue 3’13” 5’18” O.75 6 Complete 
2.  MANOJ 22 M Gluteal 4’20” 4’20” O.75 5 Near complete 
 
ABBREVIATIONS : BT – Bleeding time; CT –Clotting time; STS – Sodium tetradecyl sulphate; conc. - concentration 
 
